A randomized, phase 3, trial of interferon-α versus hydroxyurea in polycythemia vera and essential thrombocythemia

Data from the phase 3 Myeloproliferative Disorders Research Consortium 112 trial demonstrated no significant difference in 12-month complete response (CR) rates among patients with treatment-naïve, high-risk ET/PV who received hydroxyurea vs pegylated IFN-α (37% vs 35%;, respectively P = 0.80). Both arms experienced infrequent thrombotic events and disease progression, while patients in the pegylated IFN-α arm experienced more frequent grade 3/4 adverse events (46% vs 28%).